The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation
Open accessAbstract
BACKGROUND: Immunosuppressive regimens with the fewest possible toxic effects are desirable for transplant recipients. This study evaluated the efficacy and relative toxic effects of four immunosuppressive regimens. METHODS: We randomly assigned 1645 renal-transplant recipients to receive standard-dose cyclosporine, mycophenolate mofetil, and corticosteroids, or daclizumab induction, mycophenolate mofetil, and corticosteroids in combination with low-dose cyclosporine, low-dose tacrolimus, or low-dose sirolimus. The primary end point was the estimated glomerular filtration rate (GFR), as calculated by the Cockcroft-Gault formula, 12 months after transplantation. Secondary end points included acute rejection and allograft survival. RESULTS: The mean calculated GFR was higher in patients receiving low-dose tacrolimus (65.4 ml per minute) than in the other three groups (range, 56.7 to 59.4 ml per minute). The rate of biopsy-proven acute rejection was lower in patients receiving low-dose tacrolimus (12.3%) than in those receiving standard-dose cyclosporine (25.8%), low-dose cyclosporine (24.0%), or low-dose sirolimus (37.2%). Allograft survival differed significantly among the four groups (P=0.02) and was highest in the low-dose tacrolimus group (94.2%), followed by the low-dose cyclosporine group (93.1%), the standard-dose cyclosporine group (89.3%), and the low-dose sirolimus group (89.3%). Serious adverse events were more common in the low-dose sirolimus group than in the other groups (53.2% vs. a range of 43.4 to 44.3%), although a similar proportion of patients in each group had at least one adverse event during treatment (86.3 to 90.5%). CONCLUSIONS: A regimen of daclizumab, mycophenolate mofetil, and corticosteroids in combination with low-dose tacrolimus may be advantageous for renal function, allograft survival, and acute rejection rates, as compared with regimens containing daclizumab induction plus either low-dose cyclosporine or low-dose sirolimus or with standard-dose cyclosporine without induction. (ClinicalTrials.gov number, NCT00231764 [ClinicalTrials.gov].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Groth, C. G., Bäckman, L., Morales, J.-M., Calne, R., Kreis, H., Lang, P., Touraine, J.-L., Claesson, K., Campistol, J. M., Durand, D., et al. (1999) · Transplantation · doi:10.1097/00007890-199904150-00017 · Cited by 878
Strategies to Improve Long-Term Outcomes after Renal Transplantation
Pascual, M., Theruvath, T., Kawai, T., Tolkoff-Rubin, N., & Cosimi, A. B. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011295 · Cited by 844
Webster, A. C., Woodroffe, R. C., Taylor, R. S., Chapman, J. R., & Craig, J. C. (2005) · BMJ · doi:10.1136/bmj.38569.471007.ae · Cited by 587
Kreis, H., Cisterne, J.-M., Land, W., Wramner, L., Squifflet, J.-P., Abramowicz, D., Campistol, J. M., Morales, J.-M., Grinyo, J.-M., Mourad, G., et al. (2000) · Transplantation · doi:10.1097/00007890-200004150-00009 · Cited by 536
Calcineurin Inhibitor Nephrotoxicity: Longitudinal Assessment by Protocol Histology
Nankivell, B. J., Borrows, R. J., Fung, C. L.-S., O'Connell, P. J., Chapman, J. R., & Allen, R. D. M. (2004) · Transplantation · doi:10.1097/01.tp.0000128636.70499.6e · Cited by 498
Margreiter, R. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07875-3 · Cited by 450
Self-citationDean, P. G., Lund, W. J., Larson, T. S., Prieto, M., Nyberg, S. L., Ishitani, M. B., Kremers, W. K., & Stegall, M. D. (2004) · Transplantation · doi:10.1097/01.tp.0000123082.31092.53 · Cited by 332
HYPERLIPIDEMIA IN SOLID ORGAN TRANSPLANTATION
Kobashigawa, J. A., & Kasiske, B. L. (1997) · Transplantation · doi:10.1097/00007890-199702150-00001 · Cited by 314
Flechner, S. M., Kurian, S. M., Solez, K., Cook, D. J., Burke, J. T., Rollin, H., Hammond, J. A., Whisenant, T., Lanigan, C. M., Head, S. R., et al. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00627.x · Cited by 281
Cited by
Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients
Eckardt, K.-U., Kasiske, B. L., & Zeier, M. G. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02834.x · Cited by 1,499
Calcineurin Inhibitor Nephrotoxicity
Naesens, M., Kuypers, D. R. J., & Sarwal, M. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04800908 · Cited by 1,489
Linkermann, A., & Green, D. R. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1310050 · Cited by 1,103
Haas, M., Loupy, A., Lefaucheur, C., Roufosse, C., Glotz, D., Seron, D., Nankivell, B. J., Halloran, P. F., Colvin, R. B., Akalin, E., et al. (2018) · American Journal of Transplantation · doi:10.1111/ajt.14625 · Cited by 1,041
Self-citationVincenti, F., Charpentier, B., Vanrenterghem, Y., Rostaing, L., Bresnahan, B., Darji, P., Massari, P., Mondragon‐Ramirez, G. A., Agarwal, M., Di Russo, G., et al. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.03005.x · Cited by 957
Self-citationTherapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report
Brunet, M., van Gelder, T., Åsberg, A., Haufroid, V., Hesselink, D. A., Langman, L., Lemaitre, F., Marquet, P., Seger, C., Shipkova, M., et al. (2019) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000640 · Cited by 707
Long-Term Survival after Kidney Transplantation
Hariharan, S., Israni, A. K., & Danovitch, G. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2014530 · Cited by 664
Tan, J., Wu, W., Xu, X., Liao, L., Zheng, F., Messinger, S., Sun, X., Chen, J., Yang, S., Cai, J., et al. (2012) · JAMA · doi:10.1001/jama.2012.316 · Cited by 553
Wallemacq, P., Armstrong, V. W., Brunet, M., Haufroid, V., Holt, D. W., Johnston, A., Kuypers, D., Meur, Y. L., Marquet, P., Oellerich, M., et al. (2009) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e318198d092 · Cited by 468
Sawitzki, B., Harden, P. N., Reinke, P., Moreau, A., Hutchinson, J. A., Game, D. S., Tang, Q., Guinan, E. C., Battaglia, M., Burlingham, W. J., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30167-7 · Cited by 458
Self-citationMultitarget Therapy for Induction Treatment of Lupus Nephritis: A Randomized Trial
Liu, Z., Zhang, H., Liu, Z., Xing, C., Fu, P., Ni, Z., Chen, J., Lin, H., Liu, F., He, Y., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1030 · Cited by 396
Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing
Thervet, E., Loriot, M. A., Barbier, S., Buchler, M., Ficheux, M., Choukroun, G., Toupance, O., Touchard, G., Alberti, C., Le Pogamp, P., et al. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.17 · Cited by 369
Budde, K., Becker, T., Arns, W., Sommerer, C., Reinke, P., Eisenberger, U., Kramer, S., Fischer, W., Gschaidmeier, H., & Pietruck, F. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62318-5 · Cited by 359
Calcineurin inhibitors: 40 years later, can’t live without
Azzi, J. R., Sayegh, M. H., & Mallat, S. G. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1390055 · Cited by 337
Knoll, G. A., Kokolo, M. B., Mallick, R., Beck, A., Buenaventura, C. D., Ducharme, R., Barsoum, R., Bernasconi, C., Blydt-Hansen, T. D., Ekberg, H., et al. (2014) · BMJ · doi:10.1136/bmj.g6679 · Cited by 334
Self-citationEkberg, H., Bernasconi, C., Tedesco-Silva, H., Vítko, S., Hugo, C., Demirbas, A., Reyes Acevedo, R., Grinyó, J., Frei, U., Vanrenterghem, Y., et al. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02726.x · Cited by 334
Self-citationDiagnosis and prevention of chronic kidney allograft loss
Nankivell, B. J., & Kuypers, D. R. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60699-5 · Cited by 324
The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications
Weichhart, T., & Säemann, M. D. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.098459 · Cited by 323
A Systematic Review of Kidney Transplantation From Expanded Criteria Donors
Pascual, J., Zamora, J., & Pirsch, J. D. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.06.005 · Cited by 322
Neuberger, J. M., Bechstein, W. O., Kuypers, D. R. J., Burra, P., Citterio, F., De Geest, S., Duvoux, C., Jardine, A. G., Kamar, N., Krämer, B. K., et al. (2017) · Transplantation · doi:10.1097/tp.0000000000001651 · Cited by 315
Vincenti, F., Larsen, C. P., Alberu, J., Bresnahan, B., Garcia, V. D., Kothari, J., Lang, P., Urrea, E. M., Massari, P., Mondragon-Ramirez, G., et al. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03785.x · Cited by 313
Tedesco, D., & Haragsim, L. (2012) · Journal of Transplantation · doi:10.1155/2012/230386 · Cited by 302
Prevention of cardiovascular disease in adult recipients of kidney transplants
Jardine, A. G., Gaston, R. S., Fellstrom, B. C., & Holdaas, H. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61334-2 · Cited by 281
Wiebe, C., Rush, D. N., Nevins, T. E., Birk, P. E., Blydt-Hansen, T., Gibson, I. W., Goldberg, A., Ho, J., Karpinski, M., Pochinco, D., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017030287 · Cited by 280
Post-transplant diabetes mellitus in patients with solid organ transplants
Jenssen, T., & Hartmann, A. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0137-7 · Cited by 278
Roberts, M. B., & Fishman, J. A. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1189 · Cited by 277
Interleukin 2 receptor antagonists for kidney transplant recipients
Webster, A. C., Ruster, L. P., McGee, R. G., Matheson, S. L., Higgins, G. Y., Willis, N. S., Chapman, J. R., & Craig, J. C. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003897.pub3 · Cited by 268
Lebranchu, Y., Thierry, A., Toupance, O., Westeel, P. F., Etienne, I., Thervet, E., Moulin, B., Frouget, T., Le Meur, Y., Glotz, D., et al. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02615.x · Cited by 263
Organ transplantation: historical perspective and current practice
Watson, C. J. E., & Dark, J. H. (2012) · British Journal of Anaesthesia · doi:10.1093/bja/aer384 · Cited by 261
Amico, P., Hönger, G., Mayr, M., Steiger, J., Hopfer, H., & Schaub, S. (2009) · Transplantation · doi:10.1097/tp.0b013e3181a5e034 · Cited by 258
Halden, T. A. S., Kvitne, K. E., Midtvedt, K., Rajakumar, L., Robertsen, I., Brox, J., Bollerslev, J., Hartmann, A., Åsberg, A., & Jenssen, T. (2019) · Diabetes Care · doi:10.2337/dc19-0093 · Cited by 231
Baker, R. J., Mark, P. B., Patel, R. K., Stevens, K. K., & Palmer, N. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0553-2 · Cited by 211
Roles of mTOR complexes in the kidney: implications for renal disease and transplantation
Fantus, D., Rogers, N. M., Grahammer, F., Huber, T. B., & Thomson, A. W. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.108 · Cited by 208
Recipient obesity and outcomes after kidney transplantation: a systematic review and meta-analysis
Hill, C. J., Courtney, A. E., Cardwell, C. R., Maxwell, A. P., Lucarelli, G., Veroux, M., Furriel, F., Cannon, R. M., Hoogeveen, E. K., Doshi, M., et al. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv214 · Cited by 201
Andrews, L. M., Li, Y., De Winter, B. C. M., Shi, Y.-Y., Baan, C. C., Van Gelder, T., & Hesselink, D. A. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1395413 · Cited by 142
Nelson, J., Alvey, N., Bowman, L., Schulte, J., Segovia, M. C., McDermott, J., Te, H. S., Kapila, N., Levine, D. J., Gottlieb, R. L., et al. (2022) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2716 · Cited by 130
Emerging treatments for post-transplantation diabetes mellitus
Jenssen, T., & Hartmann, A. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.59 · Cited by 90
Mycophenolate Mofetil for the Treatment of Uveitis
Teoh, S. C., Hogan, A. C., Dick, A. D., & Lee, R. W. J. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2008.03.004 · Cited by 87
Metabolic consequences of modern immunosuppressive agents in solid organ transplantation
Bamgbola, O. (2016) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018816641580 · Cited by 85
Dyslipidemia and its therapeutic challenges in renal transplantation
Riella, L. V., Gabardi, S., & Chandraker, A. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04084.x · Cited by 82
Claes, K., Meier-Kriesche, H.-U., Schold, J. D., Vanrenterghem, Y., Halloran, P. F., & Ekberg, H. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr238 · Cited by 75
“As previously reported [5], the incidence of new-onset diabetes mellitus, based on adverse event reports, was 10.”
BackgroundMethodInfluentialSelf-citationUse of Empagliflozin in Recipients of Kidney Transplant: A Report of 8 Cases
Attallah, N., & Yassine, L. (2019) · Transplantation Proceedings · doi:10.1016/j.transproceed.2019.05.023 · Cited by 62
Sofroniadou, S., & Goldsmith, D. (2011) · Drug Safety · doi:10.2165/11585040-000000000-00000 · Cited by 60
Therapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges
Viana, S. D., Reis, F., & Alves, R. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/3693625 · Cited by 48
“Tacrolimus, in combination with mycophenolate mofetil or mycophenolate sodium (MMF/MPA), showed a remarkable impact on the incidence of acute rejection, which declined to around 5% and 15%, respectively, with a significant improvement in graft and patient survival to over 90% in the first year after transplantation [6…”
BackgroundThe impact of tacrolimus exposure on extrarenal adverse effects in adult renal transplant recipients
Campagne, O., Mager, D. E., Brazeau, D., Venuto, R. C., & Tornatore, K. M. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13811 · Cited by 31
Obesity after kidney transplantation-results of a KTx360° substudy
Nöhre, M., Schieffer, E., Hanke, A., Pape, L., Schiffer, L., Schiffer, M., & de Zwaan, M. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00399 · Cited by 27
Tampe, B., Tampe, D., Nyamsuren, G., Klöpper, F., Rapp, G., Kauffels, A., Lorf, T., Zeisberg, E. M., Müller, G. A., Kalluri, R., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci89632 · Cited by 24
Kim, H. D., Chang, J.-Y., Chung, B. H., Kim, C.-D., Lee, S.-H., Kim, Y. H., & Yang, C. W. (2021) · Annals of Transplantation · doi:10.12659/aot.927984 · Cited by 17
Viklicky, O., Hruba, P., Tomiuk, S., Schmitz, S., Gerstmayer, B., Sawitzki, B., Miqueu, P., Mrazova, P., Tycova, I., Svobodova, E., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0169624 · Cited by 12
Chronopharmacokinetics and Food Effects of Single-Dose LCP-Tacrolimus in Healthy Volunteers
Alloway, R. R., Trofe-Clark, J., Brennan, D. C., Kerr, J., Cohen, E. A., Meier-Kriesche, U., Stevens, D. R., Moten, M. A., & Momper, J. D. (2020) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000773 · Cited by 10
Metadata
- Authors
- Ekberg, H., Tedesco-Silva, H., Demirbas, A., Vítko, Š., Nashan, B., Gürkan, A., Margreiter, R., Hugo, C., Grinyó, J. M., Frei, U., Vanrenterghem, Y., Daloze, P., & Halloran, P. F.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-12-20
- Volume
- 357
- Issue
- 25
- Pages
- 2562-2575
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2142288396
- Cited by
- 1,810
- References
- 17
- FWCI
- 53.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.